Overactive Bladder Clinical Trial
Official title:
Validation of Instruments for Pragmatic Clinical Trials for Overatcive Bladder
A. Objectives & Hypothesis Overactive bladder (OAB) affects over 10 million adults in the
United States and each year substantial costs are incurred from private and public funds to
test the efficacy of new and existing drugs for OAB.14 However, effectiveness and adherence
data from traditional clinical trials are not generalizable to clinical practice.3, 4 In an
era of limited resources and competing demands, it is essential that cost-effectiveness data
from clinical trials be generalizable to the clinical world. Pragmatic clinical trials
measure the effectiveness of treatments in real clinical practice, and in the full spectrum
of patients that require treatment.5 Pragmatic trials require patient reported outcomes that
are valid but have low patient burden.5 The conduct of pragmatic clinical trials for OAB has
been limited by a lack of instruments that have demonstrable validity and reliability in the
typical clinical setting Pill counts, used to measure primary outcomes in most traditional
trials, are burdensome in the clinical setting.1610 The optimal instrument for measuring
utility scores, general quality of life scores for cost-effectiveness analyses for OAB, is
also not known.
Although poor adherence carries the potential for continued suffering for patients and
wasted health care resources, there is a lack of data on the clinical and economic impact of
poor adherence to treatment for OAB in real-world clinical practice. We have published
preliminary data that underscores the role of adherence and utilities in the treatment of
OAB. 3 Our hypothesis is that effectiveness, adherence, and utility preference scores can be
measured using pragmatic patient reported instruments and that poor adherence is associated
with lower effectiveness and quality of life in adults with OAB in a clinical setting.
Specifically, the overriding goal of this proposal is to validate pragmatic instruments to
measure effectiveness, adherence and utility preference scores and obtain preliminary data
on the effect of adherence and quality of life in adults undergoing treatment for overactive
bladder in a clinical setting.
Specific Aim 1: To determine the validity and responsiveness of pragmatic patient reported
outcome instruments to measure clinical effectiveness, adherence and utility preference
scores in adults undergoing treatment with anti-cholinergic medications for overactive
bladder. We will perform a prospective cohort study of adults with OAB undergoing treatment
with anti-cholinergic medication. We will compare improvement in urinary symptoms (clinical
effectiveness), adherence, and change in utility preference scores from baseline to 3 months
of treatment using new and existing 'gold standard' instruments. The results will be
informative as to which, if any of these pragmatic instruments, is useful for measuring
effectiveness, adherence, and utility preference scores in the 'real world' clinical
setting.
Specific Aim 2: To use the newly validated pragmatic instruments to measure the impact of
adherence on clinical effectiveness and health related quality of life in a real world
clinical setting in adults undergoing treatment with anti-cholinergic medications for
overactive bladder. The impact of adherence on clinical effectiveness and health related
quality of life will be measured through comparisons in adults with high and low adherence
to anti-cholinergic medication. This aim will corroborate the findings of aim 1 and
establish if pragmatic instruments are useful in measuring outcomes of effectiveness,
adherence and utility preference scores. These results will also provide preliminary data on
the effectiveness of anti-cholinergic medication and the impact of adherence on clinical
effectiveness and quality of life in the clinical setting.
;
Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
| Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
| Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
| Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
| Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
| Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
| Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
| Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
| Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
| Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
| Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
| Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
| Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
| Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
| Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
| Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
| Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
| Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
| Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
| Completed |
NCT00910520 -
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
|
Phase 3 |